References
- Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366–71
- Douglass H O, Lavin P T, Goudsmit A, Klaassen D J, Paul A R. An Eastern cooperatiave oncology group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin and 5-fluorouracil in advanced measurable gastric cancer. J Clin Oncol 1984; 2: 1372–81
- Cullinan S A, Moertel C G, Fleming T R, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253: 2061–7
- Cocconi G, DeLisi, Di Blasio B. Randomized comparison of 5-FU or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982; 66: 1263–6
- Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino M V. FAM regimen in disseminated gastric cancer. Tumori 1984; 70: 77–80
- Smith F P, Treat J A, Wooley P V, Schein P S. Chemotherapy of gastric cancer. In: Adriamycin: it's expanding role. Excerpta Med Int Congr Ser 1984; 629: 127–36
- Kim N K. Chemotherapy of advanced gastric carcinoma with 5-fluorouracil, adriamycin, mitomycin-c (FAM) and 5-fluorouracil, adriamycin, combinations (FAP): Experience in Korea. In: Adriamycin: it's expanding role. Excerpta Med Int Congr Ser 1984; 629: 137–45
- Hall S W, Benjamin R S, Griffin A C, Loo T L. Pharmacokinetics and metabolism of ftorafur in man. Proc Am Assoc Cancer Res and ASCO 1976; 17: 128
- Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil A comparative study in patients with colorectal cancer. Acta Oncol 1987; 26: 433–6
- Schein S P. The role of chemotherapy in the management of gastric and pancreatic carcinomas. Semin Oncol 1985; 12(Suppl 6)49–60
- Lavin P T, Bruckner H W, Plaxe S C. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982; 50: 2016–23